Biogen updates across its SMA research program

14 March 2022

US biotech major Biogen (Nasdaq: BIIB) today announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program aimed at improving clinical outcomes for people impacted by the disease, including the ASCEND, RESPOND and NURTURE studies.

These updates are being presented at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 13-16, 2022).

Spinraza is one of Biogen’s top-selling drugs, generating full-year 2021 global revenues of $1.9 billon. In December 2016, Ionis Pharmaceuticals (Nasdaq: IONS) licensed its Spinraza Biogen, and the drug became the first to gain approval for SMA from the US Food and Drug Administration the same month. In January this year, Biogen also exercised its option to obtain a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB115/ION306, from Ionis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK